The National Comprehensive Cancer Network Oncology Research Program announces plans to develop a program to scientifically evaluate and facilitate clinical trials on the efficacy of trifluridine and tipiracil chemotherapy.
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
